News

Claimed to be the first of its kind approval, the FDA has approved Kymriah to treat patients up to 25 years of age with B-cell precursor ALL, which

The ADC programs covered in the deal are IMGN779 and IMGN632 with an additional program also expected to be designated during the agreement term. While IMGN779 is a

Today, FORMA announced that Celgene has exercised its option, pursuant to the 2014 collaboration arrangement, to extend its strategic collaboration with FORMA by entering into a second collaboration

The companies originally entered into a commercial license and collaboration agreement in October 2011 under which Seattle Genetics had the right to exercise a co-development option for tisotumab

Merck, along with the researchers in the clinical trial service unit at the University of Oxford, reported that anacetrapib has reduced the risk of major coronary events by

The CSL subsidiary will pay an upfront payment of $91m for the acquisition. CSL Behring will get to add a pre-clinical asset in CAL-H, an HSC gene therapy

DS-5010 is a highly selective and potent RET (ret proto-oncogene) kinase inhibitor in late preclinical development. RET rearrangements and activating mutations are associated with several types of cancer,

In a separate agreement, XOMA has granted Novartis a license to its intellectual property covering the use of IL-1 beta targeting antibodies in the treatment of cardiovascular disease.

As per terms of the agreement, Gilead will pay $180.00 per Kite share in cash, representing a 29% premium to its closing price on 25 August. Based in